Office of the Director, National Institutes of Health; Notice of Meeting, 90022-90023 [2024-26426]

Download as PDF 90022 Federal Register / Vol. 89, No. 220 / Thursday, November 14, 2024 / Notices ddrumheller on DSK120RN23PROD with NOTICES1 Contact Person: Ombretta Salvucci, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W264, Rockville, Maryland 20850, 240–276–7286, salvucco@ mail.nih.gov. Name of Committee: National Cancer Institute Initial Review Group; Institutional Training and Education Study Section (F). Date: February 11–12, 2025. Time: 10:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Address: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W234, Rockville, Maryland 20850. Meeting Format: Virtual Meeting. Contact Person: Adriana Stoica, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W234, Rockville, Maryland 20850, 240–276–6368, Stoicaa2@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI SPORE (P50) Review SEP–III. Date: February 25–26, 2025. Time: 9:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Address: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W514, Rockville, Maryland 20850. Meeting Format: Virtual Meeting. Contact Person: Wlodek Lopaczynski, M.D., Ph.D., Assistant Director, Office of the Director, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W514, Rockville, Maryland 20850, 240–276–6340, lopacw@ mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI U54– SPORE–SEP II. Date: March 5–6, 2025. Time: 9:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Address: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W522, Rockville, Maryland 20850. Meeting Format: Virtual Meeting. Contact Person: Klaus B. Piontek, Ph.D., Chief, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W522, Rockville, Maryland 20850, 240–276–5413, klaus.piontek@ nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) VerDate Sep<11>2014 20:16 Nov 13, 2024 Jkt 265001 Dated: November 8, 2024. David W. Freeman, Supervisory Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–26497 Filed 11–13–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; Topics in Biological Chemistry and Biophysics. Date: December 2, 2024. Time: 9:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Razvan Liviu Cornea, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 904L, Bethesda, MD 20892, (301) 480–1955, cornearl@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Fogarty HIV Research Training Program for Low- and Middle-Income Country Institutions. Date: December 5–6, 2024. Time: 12:00 p.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Ross D. Shonat, MS, Ph.D., BS Division Director, DPPS Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4100, MSC 7814, Bethesda, MD 20892, (301) 435– 2786, ross.shonat@nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA–MH– 25–140: Streamlining mental health interventions for youth living with HIV in low and middle-income countries. Date: December 6, 2024. PO 00000 Frm 00076 Fmt 4703 Sfmt 4703 Time: 10:00 a.m. to 1:30 p.m. Agenda: To review and evaluate grant applications. Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Elia E. Ortenberg, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3108, Bethesda, MD 20892, 301–827–7189, femiaee@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: HIV/AIDS Interventions and Population and Public Health Approaches. Date: December 6, 2024. Time: 1:45 p.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Elia E. Ortenberg, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3108, Bethesda, MD 20892, 301–827–7189, femiaee@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: November 7, 2024. David W. Freeman, Supervisory Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–26427 Filed 11–13–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Office of the Director, National Institutes of Health; Notice of Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Novel and Exceptional Technology and Research Advisory Committee. The meeting will be held as a virtual meeting and will be open to the public as indicated below. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting should notify the Contact Person listed below in advance of the meeting. The meeting will be videocast and can be accessed from the NIH Videocasting and Podcasting website (https://videocast.nih.gov/). Name of Committee: Novel and Exceptional Technology and Research Advisory Committee. E:\FR\FM\14NON1.SGM 14NON1 ddrumheller on DSK120RN23PROD with NOTICES1 Federal Register / Vol. 89, No. 220 / Thursday, November 14, 2024 / Notices Date: December 3, 2024. Time: 11:00 a.m.–12:00 p.m. Agenda: The Novel and Exceptional Technology and Research Advisory Committee (NExTRAC) will receive an update from the Working Group on Engaging the Public as Partners in Clinical Research and discuss the next steps regarding the current charge to the committee, delivered in August 2023. Address: National Institutes of Health, Rockledge I, 6705 Rockledge Drive, Suite 630, Bethesda, MD 20892. Meeting Format: Virtual Meeting. Meeting Access Link: Virtual Meeting Link will be available at https://osp.od.nih.gov/ policies/novel-and-exceptional-technologyand-research-advisory-committeenextrac#tab4/. Contact Person: Jessica Tucker, Ph.D., Office of Science Policy, National Institutes of Health, 6705 Rockledge Drive, Suite 630, Bethesda, MD 20892, 301–496–9838, SciencePolicy@od.nih.gov. Any interested person may file written comments by forwarding the statement to the Contact Person listed on this notice at least two business days prior to the meeting date. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Other than name and contact information, please do not include any personally identifiable information or any information that you do not wish to make public. Proprietary, classified, confidential, or sensitive information should not be included in your comments. Please note that any comments NIH receives may be posted unredacted to the Office of Science Policy website. Information is also available on the NIH Office of Science Policy website: https:// osp.od.nih.gov/policies/novel-andexceptional-technology-and-researchadvisory-committee-nextrac#tab4, where an agenda, link to the webcast meeting, and any additional information for the meeting will be posted when available. Materials for this meeting will be posted prior to the meeting. Please check this website for updates. (Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS) Dated: November 7, 2024. David W. Freeman, Supervisory Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–26426 Filed 11–13–24; 8:45 am] BILLING CODE 4140–01–P VerDate Sep<11>2014 20:16 Nov 13, 2024 Jkt 265001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Arthritis and Musculoskeletal and Skin Diseases Advisory Council. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocasting and Podcasting website (https:// videocast.nih.gov/). The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Arthritis and Musculoskeletal and Skin Diseases Advisory Council. Date: January 28, 2025. Open: 9:30 a.m. to 3:00 p.m. Agenda: Call to Order; NIAMS Director’s Report and Discussion; Open Discussion. Address: National Institutes of Health, 31 Center Street, Bethesda, MD 20892, (Virtual Meeting). Closed: 3:15 p.m. to 3:30 p.m. Agenda: To review and evaluate grant applications and/or proposals. Address: National Institutes of Health, 31 Center Street, Bethesda, MD 20892, Virtual Meeting. Contact Person: Darren D. Sledjeski, Ph.D., Director, Division of Extramural Activities (DEA), National Institute of Arthritis and Musculoskeletal and Skin Diseases, 6701 Democracy Blvd., Bethesda, MD 20892, (301) 451–7766, darren.sledjeski@nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. PO 00000 Frm 00077 Fmt 4703 Sfmt 4703 90023 In the interest of security, NIH has procedures at https://www.nih.gov/ about-nih/visitor-information/campusaccess-security for entrance into oncampus and off-campus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: https:// www.niams.nih.gov/about/workinggroups/advisory-council, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS) Dated: November 8, 2024. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–26479 Filed 11–13–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government Owned Inventions Available for Licensing or Collaboration: Machine Learning Model for the Prioritization of Cancer Neoepitopes AGENCY: National Institutes of Health, HHS. ACTION: Notice. The National Cancer Institute (NCI), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of licensing and collaboration opportunities for the inventions listed below, which are owned by an agency of the U.S. Government and are available for license and collaboration in the U.S. to achieve expeditious commercialization of results of federally-funded research and development. FOR FURTHER INFORMATION CONTACT: Inquiries related to a collaboration opportunity should be directed to: Aida Cremesti, Senior Technology Transfer Manager, NCI, Technology Transfer Center, Email: aida.cremesti@nih.gov or Phone: 240–276–6641. Inquiries related SUMMARY: E:\FR\FM\14NON1.SGM 14NON1

Agencies

[Federal Register Volume 89, Number 220 (Thursday, November 14, 2024)]
[Notices]
[Pages 90022-90023]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-26426]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Director, National Institutes of Health; Notice of 
Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the Novel and 
Exceptional Technology and Research Advisory Committee.
    The meeting will be held as a virtual meeting and will be open to 
the public as indicated below. Individuals who plan to view the virtual 
meeting and need special assistance or other reasonable accommodations 
to view the meeting should notify the Contact Person listed below in 
advance of the meeting. The meeting will be videocast and can be 
accessed from the NIH Videocasting and Podcasting website (https://videocast.nih.gov/).

    Name of Committee: Novel and Exceptional Technology and Research 
Advisory Committee.

[[Page 90023]]

    Date: December 3, 2024.
    Time: 11:00 a.m.-12:00 p.m.
    Agenda: The Novel and Exceptional Technology and Research 
Advisory Committee (NExTRAC) will receive an update from the Working 
Group on Engaging the Public as Partners in Clinical Research and 
discuss the next steps regarding the current charge to the 
committee, delivered in August 2023.
    Address: National Institutes of Health, Rockledge I, 6705 
Rockledge Drive, Suite 630, Bethesda, MD 20892.
    Meeting Format: Virtual Meeting.
    Meeting Access Link: Virtual Meeting Link will be available at 
https://osp.od.nih.gov/policies/novel-and-exceptional-technology-and-research-advisory-committee-nextrac#tab4/.
    Contact Person: Jessica Tucker, Ph.D., Office of Science Policy, 
National Institutes of Health, 6705 Rockledge Drive, Suite 630, 
Bethesda, MD 20892, 301-496-9838, [email protected].

    Any interested person may file written comments by forwarding 
the statement to the Contact Person listed on this notice at least 
two business days prior to the meeting date. The statement should 
include the name, address, telephone number and when applicable, the 
business or professional affiliation of the interested person. Other 
than name and contact information, please do not include any 
personally identifiable information or any information that you do 
not wish to make public. Proprietary, classified, confidential, or 
sensitive information should not be included in your comments. 
Please note that any comments NIH receives may be posted unredacted 
to the Office of Science Policy website.
    Information is also available on the NIH Office of Science 
Policy website: https://osp.od.nih.gov/policies/novel-and-exceptional-technology-and-research-advisory-committee-nextrac#tab4, 
where an agenda, link to the webcast meeting, and any additional 
information for the meeting will be posted when available. Materials 
for this meeting will be posted prior to the meeting. Please check 
this website for updates.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, 
Intramural Research Training Award; 93.22, Clinical Research Loan 
Repayment Program for Individuals from Disadvantaged Backgrounds; 
93.232, Loan Repayment Program for Research Generally; 93.39, 
Academic Research Enhancement Award; 93.936, NIH Acquired 
Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, 
Undergraduate Scholarship Program for Individuals from Disadvantaged 
Backgrounds, National Institutes of Health, HHS)

    Dated: November 7, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of Federal Advisory Committee 
Policy.
[FR Doc. 2024-26426 Filed 11-13-24; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.